Patrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma
Patrick Connor Johnson, MD
Advertisement
Articles by Patrick Connor Johnson, MD
Advertisement
Latest Updated Articles
Integrating Physician Opinions Into DLBCL Treatment SelectionPublished: February 4th 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
